Cancer Moonshot℠ – Fiscal Year 2017 Funding Opportunities

Following the authorization of the 21st Century Cures Act, and the appropriation of $300 million in each FY17 and FY18, NCI released the funding opportunities (FOAs) listed below to high research initiatives that align with the efforts of the Cancer Moonshot.

Closed FOAs, FY 2017
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Canine Immunotherapy Trials and Correlative Studies (U01) RFA-CA-17-001
Adult Immunotherapy Translational Science Network Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) RFA-CA-17-002
Adult Immunotherapy Translational Science Network Consortium for PDAC Translational Studies on the Tumor Microenvironment (U01) RFA-CA-17-015
Adult Immunotherapy Translational Science Network Resource Center for the Consortium for PDAC Translational Studies (U24) RFA-CA-17-016
Adult Immunotherapy Translational Science Network Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) RFA-CA-17-005
Adult Immunotherapy Translational Science Network Cancer Immunologic Data Common (CIDC) (U24) RFA-CA-17-006
Adult Immunotherapy Translational Science Network Limited Competition: Cancer Immunotherapy Trials Network (CITN) (UM1) RFA-CA-16-501
Adult Immunotherapy Translational Science Network APRC-irAEs Associated with Cancer Immunotherapy (Admin Supp) PA-17-248
Drivers of Childhood Cancers APRC on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) PA-17-138
New Enabling Technologies PDX Development and Trial Centers (PDTCs) (U54) RFA-CA-17-003
New Enabling Technologies PDX Data Commons and Coordinating Center (PDCCC) for the PDXNet (U24) RFA-CA-17-004
New Enabling Technologies Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33) RFA-CA-17-023
New Enabling Technologies APTRC for Cancer Research (Admin Supp) PA-17-143
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity (U54) RFA-CA-17-009
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01) PAR-16-202
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21) PAR-16-201
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R21) PAR-16-236
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R01) PAR-16-238
Closed FOAs, FY 2018
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): CIDR (U24) RFA-CA-17-048
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): DMRC (U24) RFA-CA-17-047
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention (U01) RFA-CA-17-046
Adult Immunotherapy Translational Science Network Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics (R43/44) PHS2018-1/Topic 372
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy (U01) RFA-CA-17-045
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01) RFA-CA-17-051
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54) RFA-CA-17-050
Drivers of Childhood Cancers Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) RFA-CA-17-049
Generation of Human Tumor Atlases Human Tumor Atlas Network: Data Coordinating Center (U24) RFA-CA-17-036
Generation of Human Tumor Atlases Pre-Cancer Atlas (PCA) Research Centers (U2C) RFA-CA-17-035
Generation of Human Tumor Atlases Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment (R43/R44) PHS2018-1/Topic 376
Generation of Human Tumor Atlases Human Tumor Atlas Research Centers (U2C) RFA-CA-17-034
Hereditary Cancers Approaches to Identify & Care for Individuals w/ Inherited Cancer Syndromes (U01) RFA-CA-17-041
Prevention and Screening ACCSIS: Coordinating Center (U24) RFA-CA-17-039
Prevention and Screening ACCSIS (UG3/UH3) RFA-CA-17-038
Symptom Management Research Analyzing & Interpreting Clinician & Patient Adverse Event Data to Understand Tolerability (U01) RFA-CA-17-052
Symptom Management Research Coordinating Center for Research Centers for Improving Management of Symptoms (U24) RFA-CA-17-043
Symptom Management Research Bridging the Guideline Implementation Gap: Glinical Decision-Support to Improve Cancer Symptom Management (R43/R44) PHS2018-1/Topic 377
Symptom Management Research Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients (R43/R44) PHS2018-1/Topic 379
Symptom Management Research Research Centers for Improving Management of Symptoms (UM1) RFA-CA-17-042
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) RFA-CA-17-044
New Enabling Technologies Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) RFA-CA-17-032
New Enabling Technologies Supplements to Support Collaborations with the PDXNet (Admin Supp) PA-18-496
New Enabling Technologies Diagnostic Imaging for Cancer Immunotherapies (R43/R44) PHS2018-1/Topic 375
New Enabling Technologies Tools and Technologies for Monitoring RNA Modifications (R43) PHS2018-1/Topic 373
New Enabling Technologies Computer Aided Decision Support for Radiation Oncology (R43/R44) PHS2018-1/Topic 380
  • Posted: October 22, 2018

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cancer Moonshot℠ – Fiscal Year 2017 Funding Opportunities was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.